Aquestive Therapeutics, Inc.

Report azionario NasdaqGM:AQST

Capitalizzazione di mercato: US$500.4m

Aquestive Therapeutics Gestione

Criteri Gestione verificati 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Dan Barber

Amministratore delegato

US$3.5m

Compenso totale

Percentuale dello stipendio del CEO18.89%
Mandato del CEO4yrs
Proprietà del CEO0.8%
Durata media del management3.2yrs
Durata media del Consiglio di amministrazione3.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AQST: FDA Anaphylaxis Film Resubmission Timeline Will Shape Long Term Upside

Analysts have reduced their price targets for Aquestive Therapeutics to $9 per share, reflecting updated views on the timing and value contribution of Anaphylm, Libervant, and the company’s manufacturing and licensing assets following the recent FDA Complete Response Letter. Analyst Commentary Street research commentary around Aquestive Therapeutics has turned more cautious following the FDA Complete Response Letter for Anaphylm and the subsequent revision of expectations for the company’s product portfolio and assets.

AQST: Regulatory Delay And 2026 Resubmission Will Ultimately Catalyze Allergy Treatment Upside

Analysts trimmed their price targets on Aquestive Therapeutics to around $9 per share. This reflects a reassessment of timing and risk after the FDA's Complete Response Letter on Anaphylm, even as they continue to ascribe value to Anaphylm, Libervant, existing manufacturing and royalty streams, and net cash.

AQST: Regulatory Setbacks Will Ultimately Catalyze Future Allergy Treatment Upside

Aquestive Therapeutics' fair value estimate has been revised to $11.00 from $12.00 as analysts factor in updated assumptions around Anaphylm's regulatory timing and asset-level contributions following recent price target cuts and detailed sum of the parts analysis. Analyst Commentary Bullish analysts are reframing Aquestive Therapeutics primarily around the potential of Anaphylm, with updated fair value work that parses the business into distinct asset contributions.

Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval

Mar 11

AQST: FDA Feedback Will Delay Allergy Film Yet Preserve Long Term Upside

Narrative Update The Street has trimmed its average price target on Aquestive Therapeutics by $2, as analysts factor in the recent complete response letter on Anaphylm as a delay. They still view this delay as coming with a clearly defined, fixable path to a future approval decision.

AQST: Regulatory Clarity On Allergy Treatment Will Drive Future Upside Potential

Aquestive Therapeutics' analyst price target has shifted from $14.49 to $12.00 as analysts factor in the recent complete response letter for Anaphylm, a modestly higher discount rate, and recalibrated assumptions for revenue growth, profit margin, and a higher future P/E multiple reflecting updated views on the regulatory path and risk profile. Analyst Commentary Bullish analysts acknowledge the complete response letter for Anaphylm as a key setback, but several see it as a definable regulatory event rather than a permanent roadblock.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely

Feb 05
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely

AQST: FDA Letters Create Delay Yet Future Allergy Franchise Upside Remains

Analysts have revised their fair value estimate for Aquestive Therapeutics from US$7.00 to US$6.00, citing reduced revenue growth assumptions and a slightly lower future P/E multiple following recent FDA communications and updated Street research on Anaphylm. Analyst Commentary Recent Street research around Anaphylm and the FDA feedback has led several bearish analysts to revisit their models and risk assumptions for Aquestive Therapeutics.

Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. (NASDAQ:AQST) Estimates For 2026

Feb 04
Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. (NASDAQ:AQST) Estimates For 2026

AQST: FDA Review Setback Will Still Support Long Term Allergy Franchise Upside

Narrative Update Analysts have trimmed their fair value estimate for Aquestive Therapeutics to US$7.00, citing the recent FDA deficiency letter on Anaphylm and a higher chance of a complete response letter that could delay potential market entry. Analyst Commentary Recent commentary from bearish analysts has focused on the regulatory setback for Anaphylm and its potential impact on Aquestive Therapeutics' valuation and execution risk.

AQST: New Patents Will Extend Allergy Franchise Exclusivity And Support Future Upside

Analysts have lifted their price target on Aquestive Therapeutics to $12 from $9, citing new Anaphylm patents that extend brand exclusivity through at least 2037 and are viewed as meaningfully value accretive to the franchise. Analyst Commentary Recent research has centered on the new Anaphylm patents and what they might mean for Aquestive Therapeutics’ long term value.

AQST: New Patents Will Extend Key Allergy Franchise Exclusivity Through 2037

Analysts have raised their price target on Aquestive Therapeutics to $12 from $9, reflecting a higher fair value estimate of about $8 per share as they factor in stronger projected revenue growth, modestly higher risk assumptions, and the value of new patents extending Anaphylm exclusivity through at least 2037. Analyst Commentary While the latest price target increase reflects growing confidence in Aquestive Therapeutics' long term prospects, it also raises the bar for execution.

AQST: Extended Patent Protection Will Support Future Share Price Outperformance

Analysts nudged their price targets on Aquestive Therapeutics higher by roughly $3 to $12, citing newly issued patents that extend Anaphylm's exclusivity through at least 2037 and growing confidence in FDA approval prospects following the decision not to convene an advisory committee for the NDA. Analyst Commentary Street research has turned increasingly constructive on Aquestive Therapeutics as recent developments around Anaphylm have prompted upward revisions to valuation models and a reassessment of execution risk.

AQST: Multiple Patent Wins And Regulatory Progress Will Support Continued Share Price Outperformance

Analysts have raised their fair value estimate for Aquestive Therapeutics from $9.08 to $10.30. This change reflects recent patent wins for Anaphylm and improved regulatory outlooks, which are expected to enhance long-term growth and exclusivity for the company.

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Nov 15
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

AQST: Extended Patent Protection Will Drive Sustained Share Price Upside

Analysts have recently raised their price targets for Aquestive Therapeutics, with notable increases from $7 to $8 and from $9 to $12. They cite strengthened patent protection for Anaphylm and a smoother regulatory pathway as key drivers behind their more optimistic outlook.

Patent Extensions and FDA Momentum Will Support Upcoming Needle-Free Epinephrine Launch

Analysts have recently raised their price targets for Aquestive Therapeutics, with increases up to $12 per share. They cite extended patent protection for Anaphylm and positive regulatory developments as key factors supporting a more optimistic outlook.

Upcoming FDA Approval Will Enable Needle-Free Epinephrine Adoption

The analyst fair value estimate for Aquestive Therapeutics has been increased by $0.50 to $9.08. Analysts cite recent patent extensions and regulatory progress for Anaphylm as key drivers of the upward revision.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Sep 05
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts

Aug 14
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts

After Leaping 29% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar

Jul 21
After Leaping 29% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar

Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results

May 16
Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results
User avatar

FDA Approval And Anaphylm Launch Will Expand Global Reach

Success in FDA approval for Anaphylm and Libervant expansion could significantly boost revenue and market penetration.

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark

Mar 21
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark

Aquestive Therapeutics: Five Foci For 2025

Jan 06

The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25%

Dec 19
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25%

Aquestive: Rare Opportunity With Dual Platform Strategy

Nov 05

Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Sep 07
Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aug 20

Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

Aug 11
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Jul 24
What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

May 22
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

Apr 09

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 28
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1

Jan 19

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Jan 05
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dan Barber rispetto agli utili di Aquestive Therapeutics?
DataCompenso totaleStipendioUtili della società
Dec 31 2025US$3mUS$660k

-US$84m

Sep 30 2025n/an/a

-US$69m

Jun 30 2025n/an/a

-US$65m

Mar 31 2025n/an/a

-US$54m

Dec 31 2024US$4mUS$633k

-US$44m

Sep 30 2024n/an/a

-US$35m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$2mUS$600k

-US$8m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$542k

-US$54m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$1mUS$424k

-US$71m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$840kUS$410k

-US$56m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$50m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$1mUS$389k

-US$66m

Compensazione vs Mercato: La retribuzione totale di Dan ($USD 3.49M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.50M ).

Compensazione vs guadagni: La retribuzione di Dan è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Dan Barber (49 yo)

4yrs
Mandato
US$3,493,559
Compensazione

Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Daniel Barber
CEO, President & Director4yrsUS$3.49m0.82%
$ 4.1m
A. Toth
Senior VP & CFO5.4yrsUS$1.32m0.31%
$ 1.5m
Lori Braender
Corporate Secretary7.7yrsUS$1.35m0.36%
$ 1.8m
Cassie Jung
Chief Operating Officer3.5yrsNessun dato0.23%
$ 1.1m
Thomas Zalewski
Chief Legal Officer & Chief Compliance Officerless than a yearNessun datoNessun dato
Peter Boyd
Senior Vice President of Information Technology & Chief People Officer3.2yrsNessun dato0.28%
$ 1.4m
Matthew Greenhawt
Chief Medical Officerless than a yearNessun dato0.063%
$ 315.7k
Sherry Korczynski
Chief Commercial Officerless than a yearNessun dato0.20%
$ 988.6k
Melina Cioffi
Senior Vice President of Regulatory Affairsno dataNessun dato0.11%
$ 528.6k
Matthew Davis
Chief Development Officerless than a yearNessun dato0.082%
$ 410.0k
Robert Arnold
VP of Financeno dataNessun datoNessun dato
3.2yrs
Durata media
54yo
Età media

Gestione esperta: Il team dirigenziale di AQST è considerato esperto (durata media dell'incarico 3.2 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Daniel Barber
CEO, President & Director4yrsUS$3.49m0.82%
$ 4.1m
Timothy Morris
Independent Director3.8yrsUS$237.61k0.045%
$ 223.5k
Gregory Brown
Independent Chairman of the Board19.2yrsUS$274.64k0.062%
$ 307.8k
Julie Krop
Independent Director5.3yrsUS$233.22kNessun dato
John Cochran
Independent Vice Chairman of the Board22.3yrsUS$240.92k0.082%
$ 407.9k
Marco Taglietti
Independent Director5.3yrsUS$213.41k0%
$ 0
John Oppenheimer
Member of Scientific Advisory Board3.7yrsNessun datoNessun dato
Carlos Camargo
Member of Scientific Advisory Board3.7yrsNessun datoNessun dato
Ruchi Gupta
Member of Scientific Advisory Board3.7yrsNessun datoNessun dato
David Bernstein
Member of Scientific Advisory Board3.7yrsNessun datoNessun dato
David Fleischer
Member of Scientific Advisory Board3.7yrsNessun datoNessun dato
Jay Lieberman
Member of Scientific Advisory Board3.7yrsNessun datoNessun dato
3.7yrs
Durata media
64yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AQST sono considerati esperti (durata media dell'incarico 3.7 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/01 19:11
Prezzo dell'azione a fine giornata2026/05/01 00:00
Utili2025/12/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Aquestive Therapeutics, Inc. è coperta da 12 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
James MolloyAlliance Global Partners
Gary NachmanBMO Capital Markets Equity Research
Kristen KluskaCantor Fitzgerald & Co.